MEK inhibition, alone or in combination with BRAF inhibition, impairs multiple functions of isolated normal human lymphocytes and dendritic cells

@inproceedings{Vella2013MEKIA,
  title={MEK inhibition, alone or in combination with BRAF inhibition, impairs multiple functions of isolated normal human lymphocytes and dendritic cells},
  author={Laura J. Vella and Anupama Pasam and Nektaria Dimopoulos and Miles C Andrews and Anne-Laure Puaux and Jamila Louahed and Ashley J. Knights and Weisan Chan and Katherine E. Woods and Jonathan Simon Cebon},
  booktitle={Cancer immunology research},
  year={2013}
}
Combination therapy with BRAF and MEK inhibition is currently in clinical development for the treatment of BRAF-mutated malignant melanoma. BRAF inhibitors are associated with enhanced antigen-specific T-lymphocyte recognition in vivo. Consequently, BRAF inhibition has been proposed as proimmunogenic and there has been considerable enthusiasm for combining BRAF inhibition with immunotherapy. MEK inhibitors inhibit ERK phosphorylation regardless of BRAF mutational status and have been reported… CONTINUE READING